Research Overview
Human research on carnosine (and the related precursor β-alanine) in prediabetes and type 2 diabetes has most often focused on metabolic endpoints—particularly glycemic control markers such as fasting blood glucose (FBG) and hemoglobin A1c (HbA1c)—with additional, less consistent attention to lipid parameters and insulin-related indices (e.g., HOMA-IR, HOMA-β). By contrast, clinical outcomes outside metabolism (e.g., musculoskeletal health) have been minimally studied; the available randomized, double-blind trial evidence in adults with prediabetes/T2D without existing musculoskeletal disease has examined body composition, muscle strength, and tibial bone measures over 14 weeks.
The strongest synthesized evidence to date comes from a recent systematic review and meta-analysis of eight randomized controlled trials (n=377), which reports statistically significant improvements in FBG and HbA1c versus placebo and an improvement in HOMA-β (suggesting better β-cell function). Effects on BMI, fasting insulin, LDL-c, HDL-c, and HOMA-IR were not significant, while total cholesterol showed a lowering effect. In the musculoskeletal domain, the single 14-week randomized trial (2 g/day carnosine) found no meaningful benefit on grip strength, lean mass, fat measures, or tibial volumetric bone mineral density and related indices, indicating that short-term supplementation does not appear to improve musculoskeletal outcomes in this population under the studied conditions.
Key gaps include the need for larger, well-powered trials with longer follow-up to determine durability and clinical relevance of glycemic improvements, to clarify optimal dosing and whether effects differ between carnosine versus β-alanine, and to better characterize which patient subgroups benefit most. Additional research is also needed on outcomes beyond surrogate metabolic markers—such as incident diabetes, complications, inflammation/oxidative stress/AGE-related biomarkers, and patient-centered endpoints—and to reassess musculoskeletal effects in populations with existing impairments or higher baseline risk, using longer interventions and standardized outcome measures.
1. What conditions has Carnosine been studied for?
Prediabetes and type 2 diabetes (T2D/T2DM): Studied as a supplement to improve glycemic control and related metabolic markers (fasting blood glucose, HbA1c, HOMA indices).
Musculoskeletal health outcomes in prediabetes/T2D: Studied for effects on muscle strength, body composition, and bone health (e.g., grip strength, lean mass, tibial volumetric bone mineral density) in adults without existing musculoskeletal conditions.
2. Does it work in treating those conditions? Summarize the evidence.
-
Glycemic control in prediabetes/T2D: evidence suggests modest benefit.
A 2024 systematic review and meta-analysis of 8 randomized controlled trials (n=377) found supplementation with carnosine and/or β-alanine significantly reduced:
Fasting blood glucose (SMD: -0.53; 95% CI: -0.75 to -0.31; p < 0.00001).
HbA1c (SMD: -0.36; 95% CI: -0.59 to -0.12; p = 0.003).
HOMA-β improved (suggesting better β-cell function), while HOMA-IR did not reach statistical significance.
Important limitation: the meta-analysis pooled carnosine and β-alanine trials together, so the magnitude attributable to carnosine alone may be uncertain from the abstract.
-
Musculoskeletal outcomes in prediabetes/T2D: evidence does not support benefit (short term).
A randomized, double-blind trial in adults with prediabetes or T2D (2 g/day carnosine for 14 weeks; 43 completers) found no significant improvements vs placebo in:
Hand grip strength and relative strength.
Appendicular lean mass, body fat percentage, visceral fat area.
Bone outcomes at the tibia (proximal cortical vBMD, distal trabecular vBMD, stress-strain index).
The authors note longer and adequately powered trials are needed to confirm these findings.
3. What health benefits does it have?
-
Potential metabolic benefits (prediabetes/T2D):
Improved glycemic markers: reduced fasting blood glucose and HbA1c in pooled RCT evidence (meta-analysis).
Improved HOMA-β (suggesting enhanced β-cell function) in the meta-analysis.
Total cholesterol lowering was observed in the meta-analysis, while LDL-c and HDL-c were not significantly changed.
-
Mechanistic/biological rationale (not clinical proof by itself):
The musculoskeletal trial background notes carnosine has been shown to have anti-inflammatory, anti-oxidative, and anti-advanced glycation end-product (anti-AGE) properties, which are relevant to diabetes-related complications. However, that trial did not find musculoskeletal benefits over 14 weeks.
-
Benefits not supported in the provided clinical trial:
No demonstrated improvement (over 14 weeks) in muscle strength, body composition, or bone health in adults with prediabetes/T2D without musculoskeletal disease.
4. Does it have any downsides or side effects?
Side effects/adverse events are not reported in the provided abstracts. The musculoskeletal RCT and the meta-analysis summaries do not describe tolerability, adverse event rates, or specific harms.
Evidence limitations relevant to “downsides”:
Short duration in the musculoskeletal RCT (14 weeks) limits conclusions about long-term safety.
The meta-analysis includes only 8 trials and combines carnosine and β-alanine, which may increase heterogeneity and makes it harder to isolate carnosine-specific safety conclusions from the abstract alone.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
No pharmacogenomic findings are provided in the abstracts. Neither abstract reports outcomes stratified by genotype or discusses genetic variants that modify response or risk.
Practical implication: Based on the provided evidence, there is insufficient information to say whether carnosine is beneficial or harmful for specific genetic variations.
References
-
The Effect of Carnosine Supplementation on Musculoskeletal Health in Adults with Prediabetes and Type 2 Diabetes: A Secondary Analysis of a Randomized Controlled Trial
Saeede Saadati, Paul Jansons, David Scott, Maximilian de Courten, Aya Mousa (2024) -
Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Na Li, Xueqin Yan, Jiayi Lin, Meng Wu, Xingyu He (2025)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!